Connect with us


Weight Loss Drug Wegovy Reduces Sweet Cravings and Changes Taste Sensitivity


Sofia Spieler, a public relations professional from Boston, has experienced a remarkable change in her eating habits while on the weight loss drug Wegovy. Known for her lifelong sweet tooth, Spieler shared, “In the past, hearing words like ‘Sour Patch Kids’ used to make my mouth water. Now I don’t feel the need to find the treat for myself.”

The Science Behind Wegovy’s Impact


New research supports Spieler’s experience, suggesting that she is not alone in noticing these changes. Semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, has been shown to improve taste sensitivity. This change in taste perception may be one of the mechanisms through which these medications alter food preferences and contribute to weight loss.

These drugs, classified as GLP-1 (glucagon-like peptide-1) receptor agonists, appear to influence gene expression related to taste perception and modify the brain’s reward response to sweet flavors. Researcher Mojca Jensterle Sever, PhD, from the University Medical Centre in Ljubljana, Slovenia, presented these findings at the ENDO 2024 annual Endocrine Society meeting in Boston.

Study Insights

The study involved 30 women with obesity, with an average age of 33.7 and a BMI of 36.4. The participants were randomly assigned to receive either 1 milligram of semaglutide or a placebo for 16 weeks. Researchers measured taste sensitivity using taste strips with varying concentrations of sweet, salty, and bitter flavors. Functional MRI scans assessed brain responses to sweet tastes before and after meals, and small tissue samples from the participants’ tongues were analyzed.

Key findings included:

  • Improved Taste Sensitivity: Women on semaglutide showed enhanced sensitivity to sweet, salty, and bitter tastes.
  • Renewal of Taste Buds: Participants on semaglutide had improved renewal of taste buds on their tongues.
  • Brain Response to Sweetness: Increased activity was observed in a brain area responsible for reward feedback when exposed to sweet stimuli, which is often reduced in people with obesity.

While the study’s findings are promising, Sever cautioned that it is too early to generalize these results to all individuals taking semaglutide. 

Despite the positive changes in taste perception, the study did not assess the direct impact on food preferences or diet changes, leaving some questions unanswered about the clinical significance of these findings.

Real-Life Reflections


Megan Melo, MD, a family and obesity medicine doctor at Phinney Primary Care and Wellness in Seattle, echoed the study’s findings based on her clinical experience. Many of her patients on GLP-1 medications report a decreased interest in sweets and junk foods, preferring vegetables and fresh foods instead. “They want to eat vegetables and fresh food instead,” Melo said. She emphasized the importance of understanding this aspect of obesity, describing it as an “over desire for foods, especially highly processed foods that hit the ‘bliss point.’”

Melo highlighted the broader impact of reduced cravings, noting, “When people [taking the GLP-1 drugs] no longer have the cravings and chatter, not only does their eating change, but it also frees up so much brain energy.”

The new research on semaglutide offers valuable insights into how weight loss drugs like Wegovy may help modify eating behaviors by altering taste sensitivity and brain reward responses. While further research is needed to fully understand these mechanisms and their long-term effects, the findings provide a promising outlook for individuals seeking effective weight management solutions.

Have you tried Wegovy or Ozempic? How have these medications impacted your cravings and eating habits? Share your experiences and insights in the comments below. Your stories could help others on their journey to better health.


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *